NEO · CYBN.NE
Cybin Inc.
CA$15.01-CA$0.21 (-1.38%)
Cybin Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
Loading market information…
NASDAQ · MIST · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Milestone Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Milestone Pharmaceuticals Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.20. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Milestone Pharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 14, 2025 |
| -$0.31-63.16% vs estimate |
| $0.00 |
| Q4 2024 | Mar 13, 2025 | -$0.19-26.67% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.14+12.5% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $3.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$15.01-CA$0.21 (-1.38%)
Cybin Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
$2.41-$0.12 (-4.74%)
PepGen Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.1% below the high.
$1.50-$0.02 (-1.32%)
Innate Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.65% below the high.
$3.53-$0.18 (-4.88%)
Molecular Partners AG’s quoted price sits in the lower half of its reported 52-week range, 34.14% below the high.
$4.22-$0.03 (-0.71%)
Corbus Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.52% below the high.
$0.91+$0.01 (+1.6%)
Cardiff Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.45% below the high.
$1.32+$0.03 (+2.33%)
Cassava Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.49% below the high.
$0.61-$0.01 (-1.61%)
Rani Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.98% below the high.
